NextCure (NXTC) Return on Capital Employed Growth (3y) (2022 - 2026)
NextCure (NXTC) Return on Capital Employed Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -356.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -516.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -4,078.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4,967.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5,777.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,445.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 109.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 513.00 |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | -13,586.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13,586.00 |
| Mar 31, 2026 | -10,830.00 |
| Dec 31, 2025 | -12,515.00 |
| Sep 30, 2025 | -14,557.00 |
| Jun 30, 2025 | -10,129.00 |
| Mar 31, 2025 | -4,489.00 |
| Dec 31, 2024 | -4,952.00 |
| Sep 30, 2024 | -4,487.00 |
| Jun 30, 2024 | -4,247.00 |
| Mar 31, 2024 | -3,854.00 |
| Dec 31, 2023 | -3,952.00 |
| Sep 30, 2023 | -3,809.00 |
| Jun 30, 2023 | -3,907.00 |
| Mar 31, 2023 | -3,598.00 |
| Dec 31, 2022 | -2,856.00 |
| Sep 30, 2022 | -2,256.00 |
| Jun 30, 2022 | -1,857.00 |
| Mar 31, 2022 | -1,450.00 |